RhoVac AB: RhoVac AB participates at BIO-Europe Spring in Amsterdam and at two Swedish investor meetings.
RhoVac AB ("RhoVac") announced today 2 March 2018 that it will attend BIO-Europe Spring on March 12-14, 2018 in Amsterdam. Rhovac will also attend and present at Life Science Day March 7, 2018 in Gothenburg, Sweden and at BioStock Live on March 20, 2018 in Stockholm, Sweden.
RhoVac will attend BIO-Europe Spring in Amsterdam on March 12-14, 2018. BIO Europe-Spring is one of the major biotech conferences in Europe and this year, more than 1,000 companies are expected to attend the conference (https://ebdgroup.knect365.com/bioeurope-spring/). The event gives RhoVac the opportunity to present the company and its cancer vaccine RV001 for Key Opinion Leaders in industry, for investors and potential research partners.
RhoVac's CEO Anders Ljungqvist will present status and plans for the company's drug candidate RV001 on LifeScience Day in Gothenburg, Sweden March 7, 2018. The event is hosted by InWest Corporate Finance and the News Agency Finwire and registration to this event can be made via http://www.lifesciencedagen.se/anmaumllan.html.
Anders Ljungqvist will also present at BioStock Live on March 20, 2018 in Stockholm, Sweden. This event is organized by BioStock and the News Agency Direkt. Registration for this event will open March 6, 2018.For more information, please contact: Anders Ljungqvist - CEO, RhoVac AB Phone: +45 4083 2365 E-mail: firstname.lastname@example.orgAbout RhoVac AB RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com
"RhoVac utvecklar ett immunterapeutiskt läkemedel för behandling av metastaserande cancer. Läkemedlet samarbetar med kroppens immunförsvar och är riktat mot proteinet RhoC som är överuttryckt i alla metastaserande cancerceller."Medicon Village, Scheelevägen 2,
223 81 LUND +45 4083 2365 http://www.rhovac.com